Is obinutuzumab our key to improving the treatment of FL?

(2:46)

Debate: Is obinutuzumab superior to rituximab in lymphoma? - No

(14:2)

Debate: Is obinutuzumab superior to rituximab in lymphoma? - Yes

(12:52)

Follicular Lymphoma: Obinutuzumab and Chemotherapy

(2:53)

Obinutuzumab: Effective, Safe, and Worth the Cost?

(12:)

Dr. O'Connor on the Role of Obinutuzumab in Follicular Lymphoma

(1:4)

Rituximab, Obinutuzumab, and Ofatumumab in CLL

(4:7)

Dr. Abedin on the Role of Venetoclax Plus Obinutuzumab in CLL

(1:1econd)

Ibrutinib plus venetoclax followed by MRD-guided ibrutinib plus obinutuzumab in first line CLL

(4:36)

Dr. Flynn on Obinutuzumab for the Treatment of CLL

(1:11)

Dr. Valentin Goede on Obinutuzumab Versus Rituximab in CLL

(1:43)

Dr. Kambhampati on Frontline Ibrutinib Plus Obinutuzumab in CLL

(53)

Dr. Gerson on Venetoclax/Obinutuzumab Combination in CLL

(1:2)

Six-year update from CLL14: fixed-duration venetoclax + obinutuzumab for previously untreated CLL

(1:43)

Obinutuzumab \u0026 Rituximab Safety Risks

(3:18)

Dr. Davids on the Combination of Ibrutinib and Obinutuzumab in CLL

(2:34)

5-year follow-up results of CLL14: obinutuzumab + venetoclax vs obinutuzumab + chlorambucil in CLL

(59)

Dr. Woyach on 3-Year Follow-Up of Acalabrutinib/Obinutuzumab Combo in CLL

(1:20)

iLLUMINATE 4-year follow up: obinutuzumab w/ ibrutinib vs w/ chlorambucil

(1:25)

Obinutuzumab for Indolent Lymphoma

(5:24)